相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Should the CD4 threshold for starting ART be raised?
Robin Wood et al.
LANCET (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial
Andrew R. Zolopa et al.
PLOS ONE (2009)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression
Richard D. Moore et al.
CLINICAL INFECTIOUS DISEASES (2007)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
分享论文
